Summary

U.S. Pancreatic Cancer Treatment Market Growth & Trends

The U.S. pancreatic cancer treatment market is anticipated to reach USD 2.01 billion by 2030 and is expected to grow at a CAGR of 12.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.

Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due to late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues to be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.

Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues to hamper early detection and the development of personalized treatments.

Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are also playing a crucial role in addressing unmet needs in pancreatic cancer treatment.

The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively to address the critical needs of patients and families affected by this devastating disease. The next decade promises to reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.

U.S. Pancreatic Cancer Treatment Market Report Highlights

• On the basis of type, the exocrine segment held the largest revenue share of 43.25% of the U.S. pancreatic cancer treatment market in 2024. This dominance is attributed to the high prevalence of exocrine pancreatic cancer, which accounts for the majority of cases, and advancements in treatment modalities targeting this type.

• Based on treatment, the chemotherapy dominated the market with a share of 43.25% and is expected to maintain its lead during the forecast period. The widespread use of chemotherapy, particularly gemcitabine-based regimens and FOLFIRINOX, has been instrumental in managing pancreatic cancer, despite challenges such as resistance and side effects.

• Based on distribution channel, the hospital pharmacies accounted for the largest revenue share of 46.01% in 2024 and are expected to continue leading the market. This is due to the critical role hospitals play in administering complex treatment regimens, coupled with the increasing number of inpatient visits for pancreatic cancer diagnosis and treatment.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Pancreatic Cancer Treatment Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Rising Prevalence of Pancreatic Cancer
3.3.1.2. Advancements in Modern Therapeutics
3.3.1.3. Growing Investments in Pancreatic Cancer R&D
3.3.2. Market Restraints Analysis
3.3.2.1. High Cost of Advanced Therapies
3.3.2.2. Stringent Regulatory and Reimbursement Challenges
3.4. Pancreatic Cancer Treatment Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. U.S. Pancreatic Cancer Treatment Market: By Type Estimates & Trend Analysis
4.1. U.S. Pancreatic Cancer Treatment Market: Type Segment Dashboard
4.2. U.S. Pancreatic Cancer Treatment Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
4.3. Exocrine
4.3.1. Exocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Endocrine
4.4.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis
5.1. U.S. Pancreatic Cancer Treatment Market: Treatment Segment Dashboard
5.2. U.S. Pancreatic Cancer Treatment Market: By Treatment Movement Analysis, 2024 & 2030 (USD Million)
5.3. Chemotherapy
5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Radiation Therapy
5.4.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Segment Dashboard
6.2. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. Accuray Incorporated
7.4.1.1. Participant’s Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Recent Developments/ Strategic Initiatives
7.4.2. AstraZeneca
7.4.2.1. Participant’s Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Recent Developments/ Strategic Initiatives
7.4.3. Novartis AG
7.4.3.1. Participant’s Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Recent Developments/ Strategic Initiatives
7.4.4. Pfizer Inc.
7.4.4.1. Participant’s Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Recent Developments/ Strategic Initiatives
7.4.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
7.4.5.1. Participant’s Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Recent Developments/ Strategic Initiatives
7.4.6. Bristol-Myers Squibb Company
7.4.6.1. Participant’s Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Recent Developments/ Strategic Initiatives
7.4.7. Ipsen Pharma
7.4.7.1. Participant’s Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Recent Developments/ Strategic Initiatives
7.4.8. Eli Lilly and Company
7.4.8.1. Participant’s Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Recent Developments/ Strategic Initiatives
7.4.9. Siemens Healthineers AG (Varian Medical Systems, Inc., part of the company)
7.4.9.1. Participant’s Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Recent Developments/ Strategic Initiatives
7.4.10. Elekta AB
7.4.10.1. Participant’s Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Recent Developments/ Strategic Initiatives